ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SNG Synairgen Plc

4.52
0.00 (0.00%)
Last Updated: 08:00:23
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.52 4.36 4.99 - 24,733 08:00:23
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.52 9.1M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.52p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.10 million. Synairgen has a price to earnings ratio (PE ratio) of -0.52.

Synairgen Share Discussion Threads

Showing 5251 to 5269 of 99175 messages
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older
DateSubjectAuthorDiscuss
27/4/2020
20:28
But does he mean the last recruit on the trial, if so would news then be approx 2-3 weeks.
royalalbert
27/4/2020
20:15
Yes Richard said in one of the interviews that they would update on recruitment.
nobbygnome
27/4/2020
20:11
I’m surprised we have not had any update on patient recruitment I can’t imagine we will not get RNS when last patient recruited any thoughts
best1467
27/4/2020
19:56
I have to say, compared to other covid -19 shares, of late, SNG has been a dissapointment. It has been lovely for those who got in at about 25p, but since the mid 50's some time ago, it's been a wash out. A few times it's been up to mid 70's and then unfortnately fallen back. Obviously the placing did not help but puzzling it has been over 70p after this placing a couple of times and back again. Compare this action to the likes of NCYT, ACVT, ODX and others, some, who also have had placings. The difference with some i guess is that some of these shares are making something tangible like eg making test kits, whereas SNG is a binary drug treatment in the making. Success will obviously bring instant big rewards and failure a decline. In hindsight, a share purchase timed several weeks ago was not well timed, although now might well be good time to buy, where we must be close to some news release.
lukead
27/4/2020
19:53
>> likya

LOL do you see a pattern...

nobbygnome
27/4/2020
18:06
ADVFN trades don't appear to be updating correctly, only showing trades up to 591, which was 14:43... it’s been rubbish today! 🤷🏻😡


But looks like more buys, than sells 🤷🏻🤷🏻 9324;

makendon
27/4/2020
17:56
Again, look at the significant delayed buys from Friday just printed!
likya123
27/4/2020
17:36
What's he's saying.. if it shoots up to 300 pence plus...,It may come back down in the long term...
amaretto1
27/4/2020
17:08
I have disliked Fool.co.uk for a long time, as they build hype to buy and sell to suit their own means. However on this occasion I think it’s a fairly balanced report
makendon
27/4/2020
16:05
Theirs is inhaled so still could work, but they will have to get their own trial results. Probably a long way off and SNG looking like the front runner in nebuliser Covid drugs for market launch.I had a punt this morning with some Tils but a waste of time, It was 20% up but only 5 % profit due to stupid spread.
slinkyj
27/4/2020
15:59
The Regeneron and Sanofi news was out at midday fyi....Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzara® (sarilumab), an interleukin-6 (IL-6) receptor antibody, in hospitalized patients with "severe" or "critical" respiratory illness caused by COVID-19. Following a review by the Independent Data Monitoring Committee (IDMC) of all available Phase 2 and Phase 3 data, the trial will be immediately amended so that only "critical" patients continue to be enrolled to receive Kevzara 400 mg or placebo.
markinvestor
27/4/2020
15:59
Not good for TILS....
nobbygnome
27/4/2020
15:50
Many of us did the business this morning,nothing much has since changed.
bmnsa
27/4/2020
15:42
What's happened to trading. Can't see anything for nearly a hour.
cambradjones
27/4/2020
15:37
Hi Nobby


Only just seen your post, but I see someone has
kindly posted the details here..

GLA!

daffodil4
27/4/2020
15:13
Fidra yep, you can just read the posts, pnly need to be a member to reply.
royalalbert
27/4/2020
15:12
Correct fidraa no need to be a member to read all posts and prices on lse
arab3
27/4/2020
15:09
Good points from Richard IMHO....
nobbygnome
27/4/2020
15:05
It is possible to just read the lse site without becoming am member.

A search of lse Sgn chat normally gets a find!

fidra
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older

Your Recent History

Delayed Upgrade Clock